← Leaderboards
Gerald Patrick Morris
University Of California, San Diego
$3,507,794
Attributed
$4,029,827
Total exposure
6
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $993.8K · FY2010–25$1M$750K$500K$250K$0
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$4,029,827 · 6
By mechanism
R01$1,908,599 · 1
U01$606,609 · 1
K08$531,333 · 1
R21$437,458 · 1
R56$386,328 · 1
R03$159,500 · 1
Top collaborators
- Michael S Kuhns2 shared
- Hannah Kathryn Carter1 shared
Most similar at University Of California, San Diego
Same institution · by research overlap
- Ananda W Goldrath$26,441,761
- Laura Shaw$365,758
- Stephen A Spector$131,199,154
- Hannah Kathryn Carter$5,473,840
Others in their field
Top investigators on “Peptides”
- David M Nathan · Massachusetts Institute Of Technology$118,672,444
- John M Lachin · George Washington University$118,672,444
- David Heimbrook · Leidos Biomedical Research, Inc.$91,429,616
- Michael W Weiner · Northern California Institute Res &Educ$78,425,041
- Paul S. Aisen · Cognition Therapeutics, Inc.$69,846,203
- Rolf Apweiler · European Molecular Biology Laboratory$56,677,991
Research focus
PeptidesT-LymphocyteTransplantationAllogenicMouse ModelMediatingHematopoietic Stem Cell TransplantationAntigensT-Cell ReceptorCellular BiologyResponseCellsNovel StrategiesIn VivoLigandsPathologicT Cell ResponseSpecificityInnovationSolidIn VitroInvestigationGraft Vs Host DiseasePeptide/Mhc Complex
Grant awards (16)
T Cell Alloreactivity and Organ Transplant Risk Stratification Models Using High-Resolution HLA and Genomic Data$606,609
U01 · FY2025 · AI · contact PI
Use of allogeneic pMHCII-based 5MCAR-CTLs to eliminate alloreactive lymphocytes in transplant$227,708
R21 · FY2025 · AI · contact PI
Development of novel model to measure TCR signal strength in dual TCR cells$159,500
R03 · FY2025 · AI · contact PI
Dual TCR Expression Effects on Alloreactivity and Transplantation$380,730
R01 · FY2024 · AI · contact PI
Use of allogeneic pMHCII-based 5MCAR-CTLs to eliminate alloreactive lymphocytes in transplant$209,750
R21 · FY2024 · AI · contact PI
Dual TCR Expression Effects on Alloreactivity and Transplantation$381,409
R01 · FY2023 · AI · contact PI
Dual TCR Expression Effects on Alloreactivity and Transplantation$382,057
R01 · FY2022 · AI · contact PI
Dual TCR Expression Effects on Alloreactivity and Transplantation$382,292
R01 · FY2021 · AI · contact PI
Dual TCR Expression Effects on Alloreactivity and Transplantation$382,111
R01 · FY2020 · AI · contact PI
Dual TCR Expression Effects of Post-Transplant T Cell Repertoires$386,328
R56 · FY2019 · AI · contact PI
Investigation of the Molecular Basis of T Cell Alloreactivity$107,127
K08 · FY2014 · AI · contact PI
Investigation of the Molecular Basis of T Cell Alloreactivity$107,126
K08 · FY2013 · AI · contact PI
Investigation of the Molecular Basis of T Cell Alloreactivity$1
K08 · FY2013 · AI · contact PI
Investigation of the Molecular Basis of T Cell Alloreactivity$107,127
K08 · FY2012 · AI · contact PI
Investigation of the Molecular Basis of T Cell Alloreactivity$105,557
K08 · FY2011 · AI · contact PI
Investigation of the Molecular Basis of T Cell Alloreactivity$104,395
K08 · FY2010 · AI · contact PI